Key facts
- It has raised $1.0M; the latest was Seed Round ($1.0M) in Mar 2026.
- Notable investors include Development Bank of Wales, DEBRA Research, EB Research Partnership, Neem Biotech.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Mariposa Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mariposa Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mariposa Therapeutics
Developer of novel topical treatment for patients with epidermolysis bullosa simplex based in Blaenau, United Kingdom. The company focuses on extraction, synthesis and development of molecules that have proven biological activity, which can be transformed into innovative drug candidates, helping patients to treat the rare skin condition of epidermolysis bullosa simplex.
- Sector
- Healthcare
- HQ
- Cardiff, United Kingdom
- Founded
- 2020
- Employees
- 5
- Website
- mariposa.health/
- Ownership
- Privately Held (backing)
Mariposa Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mariposa Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mariposa Therapeutics in its N-PORT filings yet. We sweep new filings monthly.